Access to Evrysdi (risdiplam) treatment

In order to ensure the continuation of treatment given the circumstances, Roche has decided to provide risdiplam (Evrysdi) free of charge to all patients from Ukraine who had started treatment with this drug before the outbreak of the war.

The company will provide the drug free of charge to all such patients regardless of the mechanism through which they previously had access to it: FIREFISH clinical trial, preapproval / compassionate use programme (PAA/CU), state reimbursement in Ukraine, or out-of-pocket purchase by the patient.

Roche has called this, the Patient Support Programme (PSP).

To be able to continue treatment with risdiplam in Poland as part of this program, please follow the instructions below:

  1. Contact Roche. Send an email, send a message or make a call via WhatsApp or Telegram (details below). Mention that you are from Ukraine, that you need to continue risdiplam treatment, and provide your contact details, preferably a telephone number. You can use Ukrainian or English language.
  2. Wait for treatment confirmation. Wait for a phone call from a Roche employee. The employee will verify the data you supplied, and provide you with information about the nearest hospital where further treatment will be possible. He or she will also help to arrange a hospital appointment. Hospitals in Poland that run the Patient Support Programme are listed below.
  3. Get a GP referral. Before visiting the hospital, get a referral from your GP, i.e. a pediatrician or an internist at a primary care centre (local clinic). Find out where the nearest clinic is located, make an appointment, and then ask the GP there for a referral to a neurology (or paediatric neurology) unit for SMA therapy. This is a very important step – hospital departments in Poland do not admit patients without a referral from a general practitioner. Only a referral from a physician that sees patients under state-funded healthcare is allowed, i.e. a private consultation will not help.
  4. Attend the hospital appointment. Bring your identity documents and medical documentation for the appointment, if possible translated into Polish. At the visit, tell the doctor about any health problems. Arrive on time – if you are running late, call the hospital immediately so that the doctors can reschedule the visit and allocate the freed appointment slot to another patient.
  5. Collect the medication. You will usually receive risdiplam during the same hospital visit. Store the medication in its original packaging at 2–8°C and use as directed.

Should you face problems with the organisation of treatment, contact us and we will do our best to help.

Roche Hotline

The hotline can be contacted via email and telephone as well as WhatsApp and Telegram mobile applications.

The hotline only supports patients enrolled in the Patient Support Program. It is operated in English with the participation of a Ukrainian language translator. It is open 24 hours a day 7 days a week.

Hospitals in Poland

The Roche Patient Support Program is launched in Poland in the following hospitals:

Children with SMA:

  • Gdansk: University Clinical Center, ul. Dębinki 7, 80-952 Gdańsk
  • Lodz: Polish Mother’s Health Center, ul. Rzgowska 281/289, 93-338 Łódź
  • Poznan: Clinical Hospital, ul. Przybyszewskiego 49, 60-355 Poznań
  • Rzeszow: Provincial Clinical Hospital No. 2, ul. Lwowska 60, 35-301 Rzeszów
  • Warsaw: Children’s Health Center, al. Dzieci Polskich 20, 04-730 Warsaw

Adults with SMA:

  • Gdansk: St. Wojciech, ul. Jana Pawła II 50, 80-462 Gdańsk
  • Krakow: Szpital Specjalistyczny im. Ludwik Rydygiera, Kraków
  • Warsaw: Central Clinical Hospital, ul. Banacha 1A, 02-097 Warsaw

Hospital locations


Treatment abroad

Access to risdiplam abroad under the Patient Support Programme will be possible only in those countries and hospitals that have conducted clinical trials of risdiplam or had an open Pre-approval Access/Compassionate Use Programme.

In Europe these are currently: Belgium, Czechia, France, Germany, Greece, Italy, Netherlands, Russia, Serbia, Spain, Switzerland, Turkey, United Kingdom.

Information on enrolling in the Patient Support Programme in these countries can be obtained from the Roche Hotline.